16 related articles for article (PubMed ID: 38470208)
1. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
[TBL] [Abstract][Full Text] [Related]
2. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
Geng C; Yang G; Wang H; Wu Y; Leng Y; Zhou H; Zhang Z; Jian Y; Chen W
Leuk Lymphoma; 2021 Apr; 62(4):883-890. PubMed ID: 33275060
[TBL] [Abstract][Full Text] [Related]
3. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation.
Gao W; Li J; Wu Y; Li Y; Leng Y; Liu A; Yang G; Tian Y; Wang H; Wang G; Wu Z; Ren Z; Chen W
Ann Hematol; 2019 May; 98(5):1177-1184. PubMed ID: 30610278
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].
Yin JH; Xu TT; Wang Y; Chen WM; Liu AJ
Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1152-1157. PubMed ID: 36207970
[No Abstract] [Full Text] [Related]
5. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Frølund UC; Andersen KT; Klostergaard A; Helleberg C; Pedersen RS; Pedersen PT; Helm-Petersen S; Teodorescu EM; Preiss B; Abildgaard N; Gimsing P;
PLoS One; 2017; 12(12):e0188988. PubMed ID: 29216227
[TBL] [Abstract][Full Text] [Related]
6. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.
Chen Y; Chen Z; Cao J; Lin L; Li J
Hematology; 2024 Dec; 29(1):2329378. PubMed ID: 38470208
[TBL] [Abstract][Full Text] [Related]
7. Clinical Considerations for Immunoparesis in Multiple Myeloma.
Chahin M; Branham Z; Fox A; Leurinda C; Keruakous AR
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565407
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
